Cargando…
Biology-driven cancer drug development: back to the future
Most of the significant recent advances in cancer treatment have been based on the great strides that have been made in our understanding of the underlying biology of the disease. Nevertheless, the exploitation of biological insight in the oncology clinic has been haphazard and we believe that this...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864096/ https://www.ncbi.nlm.nih.gov/pubmed/20385032 http://dx.doi.org/10.1186/1741-7007-8-38 |
_version_ | 1782180749126926336 |
---|---|
author | Lord, Christopher J Ashworth, Alan |
author_facet | Lord, Christopher J Ashworth, Alan |
author_sort | Lord, Christopher J |
collection | PubMed |
description | Most of the significant recent advances in cancer treatment have been based on the great strides that have been made in our understanding of the underlying biology of the disease. Nevertheless, the exploitation of biological insight in the oncology clinic has been haphazard and we believe that this needs to be enhanced and optimized if patients are to receive maximum benefit. Here, we discuss how research has driven cancer drug development in the past and describe how recent advances in biology, technology, our conceptual understanding of cell networks and removal of some roadblocks may facilitate therapeutic advances in the (hopefully) near future. |
format | Text |
id | pubmed-2864096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28640962010-05-05 Biology-driven cancer drug development: back to the future Lord, Christopher J Ashworth, Alan BMC Biol Review Most of the significant recent advances in cancer treatment have been based on the great strides that have been made in our understanding of the underlying biology of the disease. Nevertheless, the exploitation of biological insight in the oncology clinic has been haphazard and we believe that this needs to be enhanced and optimized if patients are to receive maximum benefit. Here, we discuss how research has driven cancer drug development in the past and describe how recent advances in biology, technology, our conceptual understanding of cell networks and removal of some roadblocks may facilitate therapeutic advances in the (hopefully) near future. BioMed Central 2010-04-12 /pmc/articles/PMC2864096/ /pubmed/20385032 http://dx.doi.org/10.1186/1741-7007-8-38 Text en Copyright ©2010 Lord et al.; licensee BioMed Central Ltd. |
spellingShingle | Review Lord, Christopher J Ashworth, Alan Biology-driven cancer drug development: back to the future |
title | Biology-driven cancer drug development: back to the future |
title_full | Biology-driven cancer drug development: back to the future |
title_fullStr | Biology-driven cancer drug development: back to the future |
title_full_unstemmed | Biology-driven cancer drug development: back to the future |
title_short | Biology-driven cancer drug development: back to the future |
title_sort | biology-driven cancer drug development: back to the future |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864096/ https://www.ncbi.nlm.nih.gov/pubmed/20385032 http://dx.doi.org/10.1186/1741-7007-8-38 |
work_keys_str_mv | AT lordchristopherj biologydrivencancerdrugdevelopmentbacktothefuture AT ashworthalan biologydrivencancerdrugdevelopmentbacktothefuture |